- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03641950
The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm.
Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Korea
-
Seoul, Korea, Korea, Republic of, 06162
- Hugel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women at the age of 18 or older
- Subjects diagnosed with essential blepharospasm with Jankovic Rating Scale (JRS) frequency and severity sum score ≥2 at screening
- Individuals who agree to participate in the clinical study and voluntarily sign the written informed consent form
- Subjects who are cooperative, have a good understanding of the clinical study, and can comply with study procedures until the end of the study
Exclusion Criteria:
- Subjects who had received surgery such as orbicularis oculi resection or facial nerve block for the treatment of the study indication
- Subjects with a history of hypersensitivity reactions to any of the components of the investigational product (botulinum toxins, serum albumin, etc.)
- Subjects with secondary blepharospasm
- Subjects with the hemifacial spasm
- Subjects on treatment with muscle relaxants, benzodiazepines, anticholinergics, or benzamides who had changes in medication within 4 weeks prior to screening or have been on stable medication but are expected to have changes in medication while participating in the study
- Subjects who administered any of the following drugs within 7 days prior to screening: drugs with muscle relaxation activity such as aminoglycoside antibiotics or other antibiotics (spectinomycin HCl, polypeptide antibiotics, tetracycline antibiotics, lincomycin antibiotics)
- Subjects who administered medications similar to the investigational product (botulinum toxin type A) within 12 weeks
- Subjects with systemic neuromuscular junction disorders: myasthenia gravis, Lambert-Eaton syndrome, or amyotrophic lateral sclerosis
- Pregnant and lactating women
- Women of childbearing potential who are planning to become pregnant within the next 3 months or are not using an appropriate method of contraception (contraceptive methods with an annual failure rate of less than 1% if used properly and continuously, including implant, injection, oral contraceptive, at least one barrier method such as intrauterine device [IUD], hormone IUD, abstinence, or vasectomized partner)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Botulinum Toxin Type A (Botulax)
|
Recommended initial dose to be intra-muscularly injected to the medial and contralateral pretarsal orbicularis oculi of the upper eyelid and the contralateral pretarsal orbicularis oculi of the lower eyelid is 1.25-2.5U
(0.05ml ~ 0.1ml per site).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total score change from baseline at 4 weeks post-injection of Jankovic Rating scale
Time Frame: At 4 weeks post-injection
|
To evaluate the change of JRS (Jankovic Rating scale) score at 4 weeks post treatment based on baseline(0 week). JRS total score will be calculated as the sum (0~8) of two sub-scores of severity and frequency (0~4 each for severity and frequency) of blepharospasm. |
At 4 weeks post-injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total score change from baseline at 16 weeks post-injection of Jankovic Rating scale
Time Frame: At 0 weeks and 16 weeks post-injection
|
To evaluate the change of JRS (Jankovic Rating scale) score at 16 weeks post treatment based on baseline(0 week)
|
At 0 weeks and 16 weeks post-injection
|
Change from baseline at 4 weeks and 16 weeks of Disability Index
Time Frame: At 4 weeks and 16 weeks post-injection
|
To evaluate the change of Blepharospasm Disability Index at 4 weeks and 16 weeks post treatment. Functional disability assessment scale will be assessed as functional disability score. Functional disability assessment scale consists of 6 daily activities (reading, watching television, household activities (cleaning, etc.), mobility, driving, work). |
At 4 weeks and 16 weeks post-injection
|
Global Response evaluated by investigator at 4 weeks and 16 weeks after post-injection
Time Frame: At 4 weeks and 16 weeks post-injection
|
To evaluate the Investigator's assessment of global response at Weeks 4 and 16 after treatment. At Weeks 4 and 16 Visits after treatment, the investigator will assess global response on a 9-point scale from -4 (marked worsening) to +4 (Complete abolition of all signs and symptoms). |
At 4 weeks and 16 weeks post-injection
|
Change from baseline at 4 weeks and 16 weeks of WHO-Quality of Life(QOL)
Time Frame: At 4 weeks and 16 weeks post-injection
|
To evaluate the change in WHO-Quality of Life (QoL) at Weeks 4 and 16 after treatment from baseline WHOQOL will be assessed by the brief Korean version of WHOQOL (WHOQOL-BREF).
The Korean WHOQOL-BREF consists of a total of 26 subscales in 4 domains: physical health (7 items), psychological health (6 items), social relationships (3 items), and environment (8 items).
Items in each subscale are in a range from 1 (not at all or very dissatisfied) to 5 (very much or very satisfied).
|
At 4 weeks and 16 weeks post-injection
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Eyelid Diseases
- Blepharospasm
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- HG-BOT-IV3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Essential Blepharospasm
-
HugelCompletedEssential BlepharospasmKorea, Republic of
-
Medy-ToxCompletedEssential BlepharospasmKorea, Republic of
-
University of FloridaCompletedBenign Essential BlepharospasmUnited States
-
University Hospital, GrenobleCompletedBlepharospasm, Benign EssentialFrance
-
Medy-ToxCompleted
-
Silkiss Eye SurgeryJazz Pharmaceuticals; Smith-Kettlewell Eye Research Institute; Benign Essential...CompletedCBD | Blepharospasm | Blepharospasm, Benign EssentialUnited States
-
Montefiore Medical CenterNot yet recruitingHemifacial Spasm | Benign Essential Blepharospasm
-
Merz Pharmaceuticals GmbHCompletedBilateral Blepharospasm (BEB)Greece, Malaysia, Sri Lanka
-
Oxford University Hospitals NHS TrustThe Dystonia Society of the United Kingdom; Globsource UK; Statsconsultancy Ltd...CompletedBlepharospasm
-
National Institute of Neurological Disorders and...Completed
Clinical Trials on Botulinum toxin type A
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Daewoong Pharmaceutical Co. LTD.Completed
-
AllerganCompletedOveractive BladderPortugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
Brazilan Center for Studies in DermatologyCompletedWrinkles in Frontal AreaBrazil
-
HugelCompletedBenign Masseteric HypertrophyKorea, Republic of
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar Rhytides | Frown Lines Between the EyebrowsUnited States
-
Medy-ToxCompletedCervical Dystonia
-
Seton Healthcare FamilyCompleted